Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis
Adam Kinnaird(University of Alberta), Kathrin Meisterhofer(Optimum Therapeutics (United States)), Hannes Cash(Royal Free London NHS Foundation Trust), Christopher Fung(University of Alberta), Hendrik Borgmann(Goethe University Frankfurt), Arvin K. George(Johns Hopkins University), Giovanni Lughezzani(Humanitas University), A. Schreyer(Brandenburg University of Applied Sciences), Robert S. Jansen(Radboud University Nijmegen), Sangeet Ghai(University Health Network), Karsten Günzel(Medizinische Hochschule Brandenburg Theodor Fontane), Niklas Harland(STZ eyetrial), Petr Macek(Institute Mutualiste Montsouris), Julian P. Struck(Atotech (Germany)), Andreas Gusenleitner(Krankenhaus der Elisabethinen), Christian P. Pavlovich(Johns Hopkins University), Wayne Brisbane(University of California, Los Angeles), Ferdinand Luger(Krankenhaus der Elisabethinen), Joseph Brito(Dana-Farber Cancer Institute), H. Toledano, Martin Schostak(Aturo), Melis Güer(Optimum Therapeutics (United States)), Peter Incze(Oakville-Trafalgar Memorial Hospital), Neal D. Shore(Carolina Urologic Research Center), Wendy Tu(University of Alberta), Joseph Renzulli(Yale University), Tahir Durmus(Optimum Therapeutics (United States)), Laurence Klotz(Sunnybrook Health Science Centre), Moisés Rodriguez-Socarrás(Clínica Rementería), Mohammed Salah Ouertani(Centre Hospitalier Interrégional Edith Cavell), Anna L. Heinrichs(Optimum Therapeutics (United States)), Achot Guyoundouzian(Optimum Therapeutics (United States)), Cohen Eddie(Optimum Therapeutics (United States)), Christian Samtleben(Optimum Therapeutics (United States)), Jonas Bechstein(Optimum Therapeutics (United States)), Luis Felipe Urdaneta-Salegui(Clinic IMQ Zorrotzaurre), Laura Lawaczek(Optimum Therapeutics (United States)), J.G. Pereira(Clinic IMQ Zorrotzaurre)
Cited by 69
Related Papers
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
An overview of kidney stone imaging techniques
|Nature Reviews Urology|2016|389